In the evening of June 20th, Innocare (stock code 688428) announced that its innovative drug tafasitamab (Tenximapodotin) and lenalidomide have been granted priority review for biological product license application (BLA) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are not suitable for autologous stem cell transplant (ASCT), as accepted by the Center for Drug Evaluation of the National Medical Products Administration (NMPA).
诺诚健华：公司创新药生物制品许可获受理
Innocare: The company's innovative drugs and biological products have been accepted for licensing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.